B
랩지노믹스
084650KOSDAQ56.0 / 100
Reference Date: 2026-10-23
Financial Score21.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 226.0% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Labgenomics specializes in genetic molecular diagnostics, including non-invasive prenatal testing (NIPT), cancer gene screening, and chromosomal abnormality detection. As the first company in South Korea to commercialize NIPT, it leads the market with its 'MomGuard' product line and continues to expand its portfolio with innovations like the LabGun COVID-19 assay and early Alzheimer's diagnostic kits.
Number of Employees
142people
Average Salary
49.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.16Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
-35.18Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
13.61Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲10.0% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼180.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -16.1% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position5.0Point
52w mid range (46%)
Current 1,630Won52-week high 2,92552-week low 500
1-month return6.0Point
1m +226.00% (strong rise)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-30
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-30
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-30
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-30
- Neutral주식등의대량보유상황보고서(일반)2026-09-30